These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 27627984)
1. HSP32 and HSP90 Immunoexpression, in Relation to Kit Pattern, Grading, and Mitotic Count in Canine Cutaneous Mast Cell Tumors. Romanucci M; Massimini M; Ciccarelli A; Malatesta D; Bongiovanni L; Gasbarre A; Della Salda L Vet Pathol; 2017 Mar; 54(2):222-225. PubMed ID: 27627984 [TBL] [Abstract][Full Text] [Related]
2. Validation of the prognostic value of histopathological grading or c-kit mutation in canine cutaneous mast cell tumours: a retrospective cohort study. Takeuchi Y; Fujino Y; Watanabe M; Takahashi M; Nakagawa T; Takeuchi A; Bonkobara M; Kobayashi T; Ohno K; Uchida K; Asano K; Nishimura R; Nakayama H; Sugano S; Ohashi Y; Tsujimoto H Vet J; 2013 Jun; 196(3):492-8. PubMed ID: 23384436 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of exon 11 internal tandem duplications in the C-KIT proto-oncogene in Australian canine mast cell tumours. Tamlin VS; Kessell AE; Mccoy RJ; Dobson EC; Smith TS; Hebart M; Brown L; Mitrovic D; Peaston AE Aust Vet J; 2017 Oct; 95(10):386-391. PubMed ID: 28948627 [TBL] [Abstract][Full Text] [Related]
4. In situ c-KIT mRNA quantification of canine cutaneous mast cell tumours and its relationship to prognostic factors. Seung BJ; Cho SH; Kim SH; Bae MK; Lim HY; Sur JH Vet Comp Oncol; 2021 Mar; 19(1):132-139. PubMed ID: 32926564 [TBL] [Abstract][Full Text] [Related]
5. Expression of the KIT protein (CD117) in primary cutaneous mast cell tumors of the dog. Preziosi R; Morini M; Sarli G J Vet Diagn Invest; 2004 Nov; 16(6):554-61. PubMed ID: 15586571 [TBL] [Abstract][Full Text] [Related]
6. Ki67/KIT double immunohistochemical staining in cutaneous mast cell tumors from Boxer dogs. Fonseca-Alves CE; Bento DD; Torres-Neto R; Werner J; Kitchell B; Laufer-Amorim R Res Vet Sci; 2015 Oct; 102():122-6. PubMed ID: 26412531 [TBL] [Abstract][Full Text] [Related]
7. Canine subcutaneous mast cell tumors: cellular proliferation and KIT expression as prognostic indices. Thompson JJ; Yager JA; Best SJ; Pearl DL; Coomber BL; Torres RN; Kiupel M; Foster RA Vet Pathol; 2011 Jan; 48(1):169-81. PubMed ID: 21160022 [TBL] [Abstract][Full Text] [Related]
8. The value of molecular expression of KIT and KIT ligand analysed using real-time polymerase chain reaction and immunohistochemistry as a prognostic indicator for canine cutaneous mast cell tumours. Costa Casagrande TA; de Oliveira Barros LM; Fukumasu H; Cogliati B; Chaible LM; Dagli ML; Matera JM Vet Comp Oncol; 2015 Mar; 13(1):1-10. PubMed ID: 23294979 [TBL] [Abstract][Full Text] [Related]
9. CD117 immunoexpression in canine mast cell tumours: correlations with pathological variables and proliferation markers. Gil da Costa RM; Matos E; Rema A; Lopes C; Pires MA; Gärtner F BMC Vet Res; 2007 Aug; 3():19. PubMed ID: 17711582 [TBL] [Abstract][Full Text] [Related]
10. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis. Giantin M; Vascellari M; Morello EM; Capello K; Vercelli A; Granato A; Lopparelli RM; Nassuato C; Carminato A; Martano M; Mutinelli F; Dacasto M J Vet Diagn Invest; 2012 Jan; 24(1):116-26. PubMed ID: 22362941 [TBL] [Abstract][Full Text] [Related]
11. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours. Meyer A; Gruber AD; Klopfleisch R J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382 [TBL] [Abstract][Full Text] [Related]
12. CD25 is expressed by canine cutaneous mast cell tumors but not by cutaneous connective tissue mast cells. Meyer A; Gruber AD; Klopfleisch R Vet Pathol; 2012 Nov; 49(6):988-97. PubMed ID: 22446323 [TBL] [Abstract][Full Text] [Related]
13. Carboxypeptidase A3 expression in canine mast cell tumors and tissue-resident mast cells. Hämäläinen S; Kareinen L; Sukura A; Kareinen I Vet Pathol; 2022 Mar; 59(2):236-243. PubMed ID: 34894899 [TBL] [Abstract][Full Text] [Related]
14. The phosphoinositide 3-kinase pathway is crucial for the growth of canine mast cell tumors. Amagai Y; Tanaka A; Matsuda A; Oida K; Jung K; Matsuda H J Vet Med Sci; 2013; 75(6):791-4. PubMed ID: 23328607 [TBL] [Abstract][Full Text] [Related]
16. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Kiupel M; Webster JD; Kaneene JB; Miller R; Yuzbasiyan-Gurkan V Vet Pathol; 2004 Jul; 41(4):371-7. PubMed ID: 15232137 [TBL] [Abstract][Full Text] [Related]
17. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis. Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539 [TBL] [Abstract][Full Text] [Related]
18. VEGF expression in dog mastocytoma. Mederle O; Mederle N; Bocan EV; Ceauşu R; Raica M Rev Med Chir Soc Med Nat Iasi; 2010; 114(1):185-8. PubMed ID: 20509299 [TBL] [Abstract][Full Text] [Related]
19. Nanog Expression and Proliferation Indices in Canine Cutaneous Mast Cell Tumors. Joselevitch JA; Barra CN; Vargas THM; Pulz LH; Nishiya AT; Kleeb SR; Xavier JG; Catão-Dias JL; Strefezzi RF Vet Pathol; 2018 Nov; 55(6):849-852. PubMed ID: 30025495 [TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive significance of KIT protein expression and c-kit gene mutation in canine cutaneous mast cell tumours: A consensus of the Oncology-Pathology Working Group. Thamm DH; Avery AC; Berlato D; Bulman-Fleming J; Clifford CA; Hershey AE; Intile JL; Jones PD; Kamstock DA; Liptak JM; Pavuk A; Peauroi J; Powell R; Rissetto K; Valli VEO; Webster JD Vet Comp Oncol; 2019 Dec; 17(4):451-455. PubMed ID: 31264352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]